{"id":"W2808818020","doi":"10.1093/ecco-jcc/jjy079","title":"Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Janssen Biotech; Janssen Research and Development; Kyowa Hakko Kirin; Genentech; Janssen Scientific Affairs; Biogen; Celgene; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; Takeda Oncology; Tillotts Pharma; Amgen; Dr. Falk Pharma; Pfizer; Ironwood Pharmaceuticals, Incorporated; Eli Lilly and Company; Bristol-Myers Squibb; ActoGeniX; Sanofi; UCB Pharma; Abbott Laboratories","keywords":"Golimumab; Medicine; Ulcerative colitis; Extension (predicate logic); Term (time); Internal medicine; Gastroenterology; Adalimumab; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001249047,0.0003692892,0.0008177633,0.0001311839,0.0001709378,0.0003092908,0.0002267826,0.0003360143,0.001125612],"category_scores_gemma":[0.0007063948,0.0001160337,0.000986864,0.0001580017,0.0002681405,0.0003597289,0.0002953505,0.0009528093,0.0001460952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002054474,"about_ca_system_score_gemma":0.000321303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002309614,"about_ca_topic_score_gemma":0.0005568067,"domain_scores_codex":[0.999781,0.00009943683,0.00002105844,0.00002838488,0.00003119206,0.00003895194],"domain_scores_gemma":[0.9993143,0.0001447712,0.0001971249,0.00008371827,0.00004247834,0.0002175369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5713367,0.01593198,0.0260758,0.0008840499,0.001744159,0.0002625566,0.0003225136,0.0009992736,0.03105304,0.0001150174,0.001005157,0.3502697],"study_design_scores_gemma":[0.1415445,0.6935235,0.1543701,0.0001265592,0.001751338,0.0007068389,0.0001036568,0.0008601895,0.003892988,0.0001257601,0.002958847,0.00003580027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973252,0.002002179,0.000107519,0.00008466722,0.00001237078,0.00007614896,0.0001020102,0.000009089304,0.0002808194],"genre_scores_gemma":[0.9980622,0.000712994,0.0003235103,0.0001441913,0.00005744017,0.00006194981,0.0003269711,0.000002432609,0.0003082397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001249047,"threshold_uncertainty_score":0.006605685,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008796704275296016,"score_gpt":0.2409134671581696,"score_spread":0.2321167628828736,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}